PROMETIC BEGINS PATIENT ENROLLMENT FOR STUDY OF PBI-1402
ProMetic BioSciences has begun the enrollment of patients for its Phase Ib/II clinical trial of PBI-1402. The study is designed to monitor the safety and efficacy of its compound in cancer patients undergoing chemotherapy and suffering from anemia.
Several experiments demonstrated the effect of PBI-1402 in mice that had their immune system suppressed by chemotherapy. The results demonstrated that PBI-1402 promotes the growth of red blood cells, and also protects various tissues such as spleen and bone marrow from the toxic effects of chemotherapy.